Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer

Suzanne K Chambers, Shu Kay Ng, Peter Baade, Joanne F Aitken, Melissa K Hyde, Gary Wittert, Mark Frydenberg, Jeff Dunn, Suzanne K Chambers, Shu Kay Ng, Peter Baade, Joanne F Aitken, Melissa K Hyde, Gary Wittert, Mark Frydenberg, Jeff Dunn

Abstract

Background: To describe trajectories of health-related quality of life (QoL), life satisfaction, and psychological adjustment for men with prostate cancer over the medium to long term and identify predictors of poorer outcomes using growth mixture models.

Methods: One-thousand sixty-four (82.4% response) men diagnosed with prostate cancer were recruited close to diagnosis and assessed over a 72-month (6-year) period with self-report assessment of health-related QoL, life satisfaction, cancer-related distress, and prostate specific antigen anxiety. Urinary, bowel, and sexual function were also assessed using validated questionnaires.

Results: Poorer physical QOL was predicted by older age, lower education, lower income, comorbidities, and receiving hormone therapy. Lower life satisfaction was related to younger age, lower income, not being partnered, and comorbidities. Poorer psychological trajectories were predicted by younger age, lower income, comorbidities, and receiving radical prostatectomy or brachytherapy. Better urinary, bowel, and sexual function were related to better global outcomes over time. Anxiety about prostate specific antigen testing was rare.

Conclusions: Distinct trajectories exist for medium- to long-term QoL, life satisfaction, and psychological adjustment after prostate cancer; with age and socioeconomic deprivation playing a differential role in men's survivorship profile and the impact of functional status on outcomes increasing over time. These results reinforce the need for an appraisal of men's life course in addition to treatment side effects when planning survivorship care after cancer.

Keywords: cancer; longitudinal; oncology; prostate; psychological distress; quality of life.

© 2016 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Trajectory patterns identified using growth mixture models: A, quality of life SF36, physical health domain (N = 928); B, quality of life SF36, mental health domain (N = 928); C, satisfaction with life (SWL) score (N = 928); D, cancer‐related distress revised impact of event scale (RIES) score (N = 934)
Figure 2
Figure 2
Effects from the expanded prostate cancer index composite (EPIC) urinary, bowel, and sexual functions on A, SF36 physical health, B, SF36 mental health, C, satisfaction with life (SWL), and D, revised impact of event scale (RIES): a positive value of effects means that a higher EPIC function increases the score of the outcome variable, while a negative value indicates that a higher EPIC function decreases the score of the outcome variable

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2012: . Accessed 11 July 2016.
    1. Winter A, Sirri E, Jansen L, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2016. doi:
    1. Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust. 2011;194(2):73.
    1. Klaff R, Rosell J, Varenhorst E, Sandblom G. The long‐term disease‐specific mortality of low‐risk localized prostate cancer: a prospective population‐based register study over two decades. Urology. 2016;91:77–82.
    1. Surbone A, Tralongo P. Categorization of cancer survivors: why we need it. J Clin Oncol. 2016;34(28):3372–3374.
    1. Potosky AL, Davis WW, Hoffman RM, et al. Five‐year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–1367.
    1. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long‐term health‐related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68(4):600–608.
    1. Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J. The validity of the distress thermometer in prostate cancer populations. Psycho‐Oncol. 2014;23(2):195–203.
    1. Hinz A, Krauss O, Stolzenburg J‐U, Schwalenberg T, Michalski D, Schwarz R. Anxiety and depression in patients with prostate cancer and other urogenital cancer: a longitudinal study. Urol Oncol Semin Orig Investigations. 2009;27(4):367–372.
    1. Johansson E, Steineck G, Holmberg L, et al. Long‐term quality‐of‐life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group‐4 randomised trial. Lancet Oncol. 2011;12(9):891–899.
    1. Jongkamp VG, Roeloffzen EMA, Monninkhof EM, de Leeuw JRJ. Lycklama à Nijeholt AAM, van Vulpen M. Brachytherapy for prostate cancer does not influence long‐term depression rate. Brachytherapy. 2012;11(6):495–501.
    1. Korfage IJ, Essink‐Bot ML, Janssens ACJW, Schroder FH, de Koning HJ. Anxiety and depression after prostate cancer diagnosis and treatment: 5‐year follow‐up. Br J Cancer. 2006;94(8):1093–1098.
    1. Stull DE, Wiklund I, Gale R, Capkun‐Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011;32(6):818–828.
    1. Land KC, McCall PL, Nagin DS. A comparison of Poisson, negative binomial, and semiparametric mixed Poisson regression models: with empirical applications to criminal careers data. Soc Meth Res. 1996;24(4):387–442.
    1. Mplus Users Guide [computer program]. Version 6.12. Los Angeles, CA: Muthen & Muthen; 2010.
    1. Dunn J, Ng S, Holland J, et al. Trajectories of psychological distress after colorectal cancer. Psycho‐Oncol. 2013;22:1759–1765.
    1. Dunn J, Ng SK, Breitbart W, et al. Health‐related quality of life and life satisfaction in colorectal cancer survivors: trajectories of adjustment. Health Qual Life Outcomes. 2013;11(1):1.
    1. Baade PD, Aitken JF, Ferguson M, Gardiner RA, Chambers SK. Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities. BMC Cancer. 2010;10(1):452.
    1. Baade PD, Gardiner RA, Ferguson M, et al. Factors associated with diagnostic and treatment intervals for prostate cancer in Queensland, Australia: a large cohort study. Cancer Causes and Control. 2012;23(4):1–10.
    1. Baade PD, Youlden DR, Gardiner RA, et al. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland Australia. BJU Int. 2012;110(11b):E712–E719.
    1. Medical Outcomes Trust and Quality Metric Incorporated . SF‐36: SF‐36v2TM Health Survey; (IQOLA SF36v2 Standard, English (Australia), 7/03). Lincoln, RI: Medical Outcomes Trust and Quality Metric Incorporated, Health Assessment Lab; 1992. 2003
    1. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health‐related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.
    1. Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess. 1985;49(1):71–75.
    1. Weiss DS, Marmar CR. The Impact of Events Scale ‐ Revised In: Wilson JP, Keane TM, eds. Assessing Psychological Trauma and PTSD. New York, NY: The Guildford Press; 1997:399–411.
    1. Roth A, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX‐PC). Psychosomatics. 2006;47(4):340–347.
    1. Roth AJ, Rosenfeld B, Kornblith AB, et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer. 2003;97(11):2910–2918.
    1. Muthén B. Latent variable analysis In: The Sage Handbook of Quantitative Methodology for the Social Sciences. Thousand Oaks, CA: Sage Publications; 2004:345–368.
    1. Infurna FJ, Luthar SS. Resilience to major life stressors is not as common as thought. Perspect Psychol Sci. 2016;11(2):175–194.
    1. Reinecke J, Seddig D. Growth mixture models in longitudinal research. AStA Adv Stat Anal. 2011;95(4):415–434.
    1. Jung T, Wickrama K. An introduction to latent class growth analysis and growth mixture modeling. Soc Personal Psychol Compass. 2008;2(1):302–317.
    1. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 2004;81.
    1. Curran PJ, Obeidat K, Losardo D. Twelve Frequently asked questions about growth curve modeling. J Cogn Dev. 2010;11(2):121–136.
    1. Chambers SK, Lowe A, Hyde MK, et al. Defining young in the context of prostate cancer. Am J Mens Health. 2015;9(2):103–114.
    1. Song L, Ji Y, Nielsen ME. Quality of life and health status among prostate cancer survivors and noncancer population controls. Urology. 2014;83(3):658–663.
    1. Song L, Mishel M, Bensen JT, et al. How does health literacy affect quality of life among men with newly diagnosed clinically localized prostate cancer? Cancer. 2012;118(15):3842–3851.
    1. Dunn J, Steginga S, Rosoman N, Millichap D. A review of peer support in the context of cancer. J Psychosoc Oncol. 2003;21(2):55–67.
    1. Steginga SK, Pinnock C, Gardner M, Gardiner R, Dunn J. Evaluating peer support for prostate cancer: the prostate cancer peer support inventory. BJU Int. 2005;95(1):46–50.
    1. Chambers S, Hyde MK, Zajdlewicz L, et al. Measuring masculinity in the context of chronic disease. Psychol Men Masc. 2015;17(3):228–242.
    1. Chambers SK, Scuffham PA, Baade PD, et al. Advancing prostate cancer survivorship research in Australia. Cancer Forum. 2015;39(3):204–209.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever